Cover storyCDMO Trends 2026: What’s Driving Mergers And Acquisitions
CDMO trends 2026 show a structural consolidation wave — bigger deals, sharper specialization, and rising onshoring pressure reshaping manufacturing.
Cover storyCDMO trends 2026 show a structural consolidation wave — bigger deals, sharper specialization, and rising onshoring pressure reshaping manufacturing.

FDA grants accelerated approval to Ultragenyx's Genglycos, the first gene therapy for GSD1a, based on a 48-week surrogate endpoint trial.

Tilray scales cultivation to 275 MT across EU-GMP-certified sites in Canada and Portugal, reshaping international medical cannabis supply chains.

FDA grants Kyverna's miv-cel RMAT designation for naSPMS, adding a third indication to an autologous CAR T manufacturing platform already under BLA review.

Strides Pharma's Bengaluru site receives FDA EIR, closing the inspection cycle with no outstanding compliance actions.
Latest edition

Sep 28
Feb 03From native content to event partnerships, we help brands earn the attention of a hard-to-reach, senior audience — without breaking the reading experience.
See partnership options →Explore expert-led guides crafted for pharma professionals. Log in to download and stay ahead.








Join thousands of pharma professionals getting our sharpest reporting, briefings and guides — free.
